Clinical Trial

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-04-28
Trial Details
NCT Number NCT06920433
Lead Sponsor Zhejiang University
Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions Systemic Lupus Erythematosus
Enrollment 18 participants
Start Date 2025-04-08
Primary Completion 2026-04 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-05-01